How does NATURLAND's PB Ratio compare to its peers?

Insufficient data to calculate NATURLAND's Price-To-Book Ratio vs. peers for valuation analysis.

How does NATURLAND's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?

Insufficient data to calculate NATURLAND's Price-To-Book Ratio vs. industry for valuation analysis.

What is NATURLAND's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate NATURLAND's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of NATURLAND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate NATURLAND's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

NATURLAND Stock Overview

Naturland Holding Vagyonkezelo es Befektetesi Nyilvanosan Makodo Reszvenytarsasag manufactures and sells pharmaceutical products in Hungary. More details

NATURLAND fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Has not reported any financial data

Does not have a meaningful market cap (HUF34B)

My Notes

Capture your thoughts, links and company narrative

Naturland Holding Vagyonkezelo es Befektetesi Nyilvanosan Mukodo Reszvenytarsasag Competitors

NUTEX Investments

BUSE:NUTEX

Ft3.5b

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt

BUSE:RICHTER

Ft1.9t

Cinclus Pharma Holding

OM:CINPHA

SEK 944.5m

Jeil Pharma Holdings

KOSE:A002620

₩121.7b

Price History & Performance

Summary of share price highs, lows and changes for Naturland Holding Vagyonkezelo es Befektetesi Nyilvanosan Mukodo Reszvenytarsasag
Historical stock prices
Current Share Price	Ft2,440.00
52 Week High	Ft2,460.00
52 Week Low	Ft2,260.00
Beta	0
1 Month Change	2.52%
3 Month Change	n/a
1 Year Change	7.96%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	132.38%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	NATURLAND	HU Pharmaceuticals	HU Market
7D	0.8%	-7.3%	-1.3%
1Y	8.0%	-3.3%	20.5%

Return vs Industry: NATURLAND exceeded the Hungarian Pharmaceuticals industry which returned -3.3% over the past year.

Return vs Market: NATURLAND underperformed the Hungarian Market which returned 20.5% over the past year.

Price Volatility

Is NATURLAND's price volatile compared to industry and market?
NATURLAND volatility
NATURLAND Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	3.5%
10% most volatile stocks in HU Market	9.2%
10% least volatile stocks in HU Market	2.2%

Stable Share Price: NATURLAND's share price has been volatile over the past 3 months compared to the Hungarian market.

Volatility Over Time: Insufficient data to determine NATURLAND's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2012	n/a	Emil Sántó	naturlandholding.hu

Naturland Holding Vagyonkezelo es Befektetesi Nyilvanosan Makodo Reszvenytarsasag manufactures and sells pharmaceutical products in Hungary. It sells its products under the Naturland brand name. The company was founded in 2012 and is based in Budapest, Hungary.

Naturland Holding Vagyonkezelo es Befektetesi Nyilvanosan Mukodo Reszvenytarsasag Fundamentals Summary

How do Naturland Holding Vagyonkezelo es Befektetesi Nyilvanosan Mukodo Reszvenytarsasag's earnings and revenue compare to its market cap?
NATURLAND fundamental statistics
Market cap	Ft33.71b
Earnings (TTM)	Ft0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is NATURLAND overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NATURLAND income statement (TTM)
Revenue	Ft0
Cost of Revenue	Ft0
Gross Profit	Ft0
Other Expenses	Ft0
Earnings	Ft0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did NATURLAND perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 05:09
End of Day Share Price	2024/12/20 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Naturland Holding Vagyonkezelo es Befektetesi Nyilvanosan Mukodo Reszvenytarsasag is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution